Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Hyleukin-7 for the treatment of chemotherapy induced lymphopenia and cancer

Trial Profile

A clinical trial of Hyleukin-7 for the treatment of chemotherapy induced lymphopenia and cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs GX I7 (Primary)
  • Indications Cancer; Chemotherapy-induced damage; Leucopenia
  • Focus Adverse reactions
  • Sponsors I-MAB Biopharma
  • Most Recent Events

    • 15 Nov 2018 New trial record
    • 12 Nov 2018 According to an I-MAB Biopharma media release, the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for TJ107 (GX-I7, HyLeukin, Hyleukin-7), for the treatment of chemotherapy induced lymphopenia and cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top